evipedia.ai
← Back

Etomerzol for Health & Longevity

Evidence Review created on 10/04/2026 using AI4L / Opus 5.5

Also known as: Ethomersol, Etomersol, Ethomerzol, Etomerzole, Ethomersole, Tomerzol, Tomersol, 5-ethoxy-2-ethylthiobenzimidazole, 5-ethoxy-2-ethylmercaptobenzimidazole

Motivation

Etomerzol (also spelled ethomersol) is a synthetic compound from the same chemical family as bemitil, a Soviet performance drug. It was designed to help the body keep working when oxygen is scarce or physical strain is extreme, mainly by supporting how cells produce energy. It draws interest from people who look for ways to stay resilient under heavy exertion, altitude, and illness, and who follow the wider revival of Soviet-era performance compounds.

The compound was created for military medicine in the Soviet Union and first tested in poisoned patients shortly before that state collapsed, after which its development stalled. Almost all of its research exists only in Russian, and it has never been approved as a medicine anywhere. Today it circulates only as a laboratory chemical, which makes it largely unknown outside specialist circles.

This review examines what is actually known about Etomerzol: how it is thought to work, what the human and animal studies measured, what risks have been recorded, and how far that evidence reaches for a health- and longevity-focused adult considering an unapproved research compound.

Benefits - Risks - Protocol - Conclusion

This section lists the most substantial accessible overviews and primary reports on Etomerzol.

None of the six priority sources (FoundMyFitness, Peter Attia, Huberman Lab, Chris Kresser, Life Extension, Lifespan.io) has published content on Etomerzol; the compound is essentially absent from English-language health media.

Only three items are listed: the remaining literature consists of narrow Russian-language rodent experiments, cited in the sections below, that do not provide an overview of the compound.

Grokipedia

No Grokipedia article on Etomerzol exists.

Examine

No Examine article on Etomerzol exists. Examine.com covers supplements and nutrition and does not typically cover unapproved investigational drugs such as Etomerzol.

ConsumerLab

No ConsumerLab article on Etomerzol exists. ConsumerLab tests marketed supplements and does not typically cover unapproved investigational drugs such as Etomerzol.

Systematic Reviews

No systematic reviews or meta-analyses for Etomerzol were found on PubMed as of 2026-09-30.

Neither the claimed benefits nor the principal risks of Etomerzol are covered by any systematic review or meta-analysis.

Mechanism of Action

Etomerzol (5-ethoxy-2-ethylthiobenzimidazole) is a benzimidazole (a two-ring nitrogen-bearing chemical scaffold) relative of bemitil. It is classed as an actoprotector (a compound that sustains physical work capacity without raising oxygen use) and an antihypoxant (a compound protecting cells when oxygen is scarce). All proposed mechanisms come from animal and cell studies:

  • Energy production: preserves mitochondrial (cellular power-plant) respiration and limits uncoupling of oxidative phosphorylation (the oxygen-driven step making cellular energy) (Oliynyk & Oh, 2012).
  • Antioxidant: lowers lipid peroxidation (oxidative damage to membrane fats) and raises antioxidant enzymes; lab data conflict on direct radical scavenging (Mironova et al., 2003; Plotnikov et al., 1992).
  • Circulation: blocks calcium channels (pores that trigger vessel contraction), widening brain vessels, and inhibits platelet aggregation (clumping of clotting cells) (Plotnikova et al., 1992).
  • Oxygen delivery: lowers hemoglobin’s grip on oxygen, releasing more to tissues (Plotnikova et al., 1991).
  • Repair: speeds protein, genetic-material and glycogen (stored sugar) synthesis in regenerating liver (Gaivoronskaia et al., 2000).

A competing reading attributes these effects to nonspecific stress protection; no molecular target has been identified.

Pharmacology: half-life (time for blood levels to halve) is about 2 hours after injection in volunteers and 8–9 hours in poisoned patients (Aksenov, 1996). Selectivity is undefined. Distribution is rapid; repeated dosing accumulates drug in brain, heart, kidneys, lungs and fat (Sergeeva & Gulyaeva, 2008). Metabolism is mainly in the liver, as for other benzimidazoles (Spasov et al., 2002); the CYP (cytochrome P450, drug-clearing liver enzymes) enzymes involved are uncharacterized.

Historical Context & Evolution

Etomerzol grew out of the antihypoxant program of the Department of Pharmacology at the Military Medical Academy in Leningrad, led by Vasiliy Vinogradov. From the 1960s, F. Yu. Rachinsky’s team synthesized sulfur-containing compounds, and Shabanov’s history lists Etomerzol with gutimin, amtizole, bemitil and almid (Shabanov, 2024); a 1996 dissertation (Aksenov, 1996) credits its synthesis to the Ukrainian Academy of Sciences.

The original intended use was military and disaster medicine: keeping soldiers, sailors and rescuers functional under oxygen shortage, heat, heavy exertion and poisoning. In the late 1980s Etomerzol was advanced as a water-soluble relative of bemitil so it could be injected in military toxicology, surgery and resuscitation (Oliynyk & Oh, 2012).

Clinical studies in 1990–91 in patients poisoned by organophosphate insecticides (pesticides that block a key nerve enzyme) reported faster recovery, but the acidic solution caused frequent injection-site complications (Oliynyk & Oh, 2012). After the Soviet Union dissolved in 1991, clinical development stopped. A 1996 dissertation (Aksenov, 1996) added volunteer, pharmacokinetic and poisoning-recovery data; later work, through 2012, was confined to rodents.

Almost all studies come from the institutions that developed the compound, an institutional interest in its adoption. Interest for health optimization stems from the actoprotector idea of raising endurance and recovery without stimulant-style depletion, and from renewed attention to Soviet-era compounds such as bemitil and bromantane. What changed was not new contrary evidence but the loss of institutional sponsorship; the original findings were never replicated or refuted in internationally published trials.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human evidence is a single small single-blind controlled study in poisoned patients and one volunteer exertion study, both reported only in a dissertation, with no replicated trial.

Medium 🟩 🟩

Faster Recovery After Organophosphate Poisoning ⭕️ Not Central to Health & Longevity

In a single-blind controlled study of 29 patients recovering from carbophos (malathion) poisoning, Etomerzol administered intramuscularly alongside standard care sped recovery of muscle strength, breath-holding capacity, heart function indices, liver and kidney markers, and self-rated well-being (Aksenov, 1996). The proposed basis is renewed protein synthesis and energy production. The study is small, not peer-reviewed, and ran within the developing institution; Oliynyk & Oh, 2012 summarize these studies as generally positive. It bears on recovery from acute poisoning, not on healthy aging.

Magnitude: Hand-grip strength on day 7 of severe poisoning reached 77% of normal with Etomerzol versus 46% in controls; overall functional normalization occurred by day 10 versus day 16 (Aksenov, 1996).

Low 🟩

Endurance and Recovery During Prolonged Exertion

In healthy volunteers performing 6- and 24-hour physical workloads, Etomerzol improved static and dynamic endurance, mental performance and recovery, reportedly exceeding bemitil during 24-hour loads. Controls are unclear in a single dissertation study; the class rationale is reviewed by Oliynyk & Oh, 2012.

Magnitude: Direction only: improved endurance and faster recovery during 6- and 24-hour workloads in healthy volunteers; the available report gives no outcome figure for these endpoints (Aksenov, 1996).

Speculative 🟨

Brain Protection During Reduced Blood Flow

In rats and cats with blocked brain arteries, Etomerzol restored blood flow after reopening and reduced brain swelling and oxygen deficit (Plotnikova et al., 1991; Vaizova et al., 1994). Basis is animal data only.

Liver Protection and Regeneration

Etomerzol sped liver regrowth after partial surgical removal in rats (Gaivoronskaia et al., 2000) but protected toxin-injured liver less than comparators (Dubovaia et al., 1996). Basis is animal data only.

Tolerance of Acute Oxygen Shortage

Etomerzol protected rats during simulated high-altitude hypoxia (low tissue oxygen) and recovery (Kosolapov et al., 1996), and lowered hemoglobin’s oxygen binding (Plotnikova et al., 1991). Basis is animal data only.

Recovery After Traumatic Brain Injury ⭕️ Not Central to Health & Longevity

After head trauma in rats, Etomerzol reduced behavioral deficits and brain metabolic disturbances (Zarubina & Shabanov, 2005) and lowered oxygen demand (Novikov et al., 2008). Basis is animal data only; it bears on head-injury care.

Support During Severe Blood Loss ⭕️ Not Central to Health & Longevity

In cats with severe blood loss, Etomerzol added to saline infusion improved circulation (Udovichenko et al., 1991). Basis is animal data only; it bears on trauma care, not healthy aging.

Immune Activation

Etomerzol stimulated mouse macrophages (immune scavenger cells) (Ratnikov & Ratnikova, 1991) and antibody-forming spleen cells in stressed rats (Okovityi & Gaivoronskaia, 2002). Basis is animal data only.

Chromosome Protection

In cultured human lymphocytes (white blood cells), tomerzol (Etomerzol) reduced chromosome damage caused by photrin (a DNA-damaging alkylating drug) and the antibacterial dioxidine (Arutyunyan et al., 1994). Basis is cell-culture data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic (gene-drug response) study exists. Because the enzymes that clear Etomerzol are unidentified, no gene variant can yet be linked to stronger or weaker benefit.
  • Innate hypoxia resistance: Rats with both low and high inborn tolerance to oxygen shortage improved after brain trauma, but behavioral responses differed, suggesting individual resistance shapes the effect (Zarubina & Shabanov, 2005).
  • Baseline biomarkers: Benefits appeared where oxidative-stress markers, liver enzymes, bilirubin and kidney markers were deranged by poisoning or ischemia (restricted blood supply). People with normal baselines have less to correct; the volunteer study is the only healthy-baseline data (Aksenov, 1996).
  • Sex: The poisoning study (Aksenov, 1996) enrolled men and women without sex-specific analysis, and most animal work used male rats. Sex-based differences in benefit are unknown.
  • Pre-existing conditions: Observed benefits were confined to acute stress states: poisoning, brain ischemia, head trauma, blood loss and liver injury. Whether chronic conditions of aging respond is untested.
  • Age: The poisoning study’s mean age was about 45 years (Aksenov, 1996). No data exist for adults over 65, whose declining mitochondrial function could theoretically change response in either direction.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-Site Reactions

The injectable hydrochloride solution is strongly acidic (pH about 3). In the 1990–91 clinical studies, intravenous injection frequently caused phlebitis (vein inflammation) and acute pain, while intramuscular injection caused aseptic inflammation (non-infectious tissue inflammation), sometimes progressing to necrosis (tissue death) (Oliynyk & Oh, 2012). A later volunteer study reported moderate injection pain as the only adverse event (Aksenov, 1996). The problem is formulation-driven and applies to any self-prepared unbuffered solution.

Magnitude: Direction plus conditions: complications were described as frequent after intravenous or intramuscular injection of the unbuffered acidic solution; the available reports give no incidence figure.

Medium 🟥 🟥

No risk reaches Medium: apart from injection-site reactions, no adverse event has been documented in an Etomerzol trial; the remaining human data are one pharmacokinetic comparison and class reports for bemitil.

Low 🟥

Class Effects Shared With Bemitil

The close analog bemitil can cause nausea, stomach discomfort, irritability, shortened sleep, headache and facial flushing (Oliynyk & Oh, 2012). Whether Etomerzol, taken orally or long-term, shares these effects is untested; the evidence is indirect.

Magnitude: Not quantified in available studies. No Etomerzol study has reported rates for these effects, and bemitil sources describe them only qualitatively.

Drug Accumulation With Impaired Liver or Kidney Function

Half-life rose about fourfold in poisoned patients with liver and kidney injury (Aksenov, 1996), and repeated dosing in rats accumulated drug in brain, heart, kidneys, lungs and fat (Sergeeva & Gulyaeva, 2008). Clinical consequences of accumulation are unstudied.

Magnitude: Half-life about 2.1 hours in healthy volunteers versus 7.8–9.0 hours in poisoned patients (Aksenov, 1996).

Speculative 🟨

Blood Pressure Lowering

Calcium-channel blockade and vessel widening in rat brain vessels (Plotnikova et al., 1992) suggest possible blood pressure lowering and dizziness. Basis is mechanistic animal data only.

Bleeding Tendency

Etomerzol inhibited platelet clumping triggered by several agents in rats (Plotnikova et al., 1992), implying possible added bleeding risk. Basis is mechanistic animal data only.

Low Blood Sugar

Bemitil is contraindicated in hypoglycemia (low blood sugar) (Oliynyk & Oh, 2012). Whether Etomerzol lowers glucose in people is unknown. Basis is class extrapolation only.

Unknown Long-Term Toxicity

No human exposure beyond about 10 days is reported, and no public chronic, reproductive or cancer-risk toxicity data exist. Basis is absence of data, not observed harm.

Risk-Modifying Factors

  • Genetic polymorphisms: No data exist. With clearing enzymes unidentified, slow-metabolizer variants of CYP genes cannot be excluded as a cause of accumulation.
  • Baseline biomarkers: Elevated liver enzymes, bilirubin or creatinine signal slower clearance, as in poisoned patients whose half-life rose about fourfold (Aksenov, 1996). Low baseline glucose or platelet counts may amplify theoretical risks.
  • Sex: No sex-specific safety data exist. Pregnancy and breastfeeding exposure are entirely unstudied.
  • Pre-existing conditions: Bleeding disorders, low blood pressure, tendency to hypoglycemia, and liver or kidney disease may amplify theoretical risks. Fragile veins raise injection-site complications.
  • Age: Age-related decline in liver and kidney function after 65 may prolong exposure. No older-adult safety data exist.

Key Interactions & Contraindications

  • Blood pressure drugs and calcium-channel blockers (amlodipine, verapamil, diltiazem): Caution. Possible additive blood pressure lowering with dizziness or fainting, based on animal calcium-channel blockade. Home blood pressure checks during the first days detect it.
  • Anticoagulants (clot-slowing drugs: warfarin, apixaban) and antiplatelet drugs (clopidogrel): Caution. Possible added bleeding from platelet inhibition seen in animals. With warfarin, INR (international normalized ratio, a clotting-time test) checks within the first week detect the effect.
  • Barbiturates (sedatives that slow brain activity: phenobarbital, butalbital): Avoid. Bemitil is contraindicated with barbiturates (Oliynyk & Oh, 2012), implying altered sedation or drug handling; the mechanism is unreported and the contraindication is extrapolated to Etomerzol. Avoiding the combination is the only known mitigation.
  • Glucose-lowering drugs (insulin, glipizide, glibenclamide): Caution. Class concern for hypoglycemia with confusion or fainting. Fingerstick glucose checks during the first days detect it.
  • Narrow-margin drugs (digoxin, lithium, phenytoin): Monitor. Benzimidazoles are extensively metabolized by the liver, with interaction potential (Spasov et al., 2002); Etomerzol’s enzymes are unknown, so blood levels may shift. Drug-level testing detects it.
  • Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: aspirin, ibuprofen, naproxen): Caution. Additive platelet inhibition may increase bruising and gastrointestinal bleeding. Limiting concurrent use lowers risk.
  • Antiplatelet supplements (fish oil, Ginkgo biloba, high-dose vitamin E, garlic extract): Caution. Additive bleeding tendency. Pausing these supplements during a course removes the overlap.
  • Blood-pressure-lowering supplements (magnesium, beetroot nitrate, hawthorn): Monitor. Additive lowering of blood pressure with dizziness. Home readings detect it.
  • Other actoprotectors and antihypoxants (bemitil, bromantane, Mexidol, Hypoxen): Avoid stacking. Overlapping mechanisms and no combination safety data; effects and side effects may add unpredictably.
  • Alcohol: Caution. Added liver burden in a compound cleared by the liver; heavy drinking may prolong exposure. Abstaining during a course removes the overlap.
  • High-altitude exposure or hypoxic training: Monitor. Lower hemoglobin oxygen binding could alter oxygen loading in the lungs at altitude. Pulse oximetry (fingertip blood-oxygen measurement) tracks it.

Populations who should avoid Etomerzol:

  • Pregnant or breastfeeding women (no reproductive safety data)
  • People under 18 years
  • People with bleeding disorders, or within 7 days before or after surgery
  • People with low blood pressure (systolic below 90 mmHg)
  • People with recurrent hypoglycemia or insulin-treated diabetes
  • People with moderate or severe liver impairment (Child-Pugh Class B or C, a liver-function severity score)
  • People with severe kidney impairment (eGFR, estimated glomerular filtration rate, a kidney-filtration measure, below 30 mL/min/1.73 m²)
  • Competitive athletes subject to anti-doping testing
  • People taking barbiturates

Risk Mitigation Strategies

  • No unbuffered injection: Injection-site necrosis and phlebitis followed the pH-3 solution; injected use in studies was clinically supervised, and non-injected routes avoid this risk entirely.
  • Short courses only: Limiting exposure to the 3–10 day courses studied in humans avoids the unknown long-term toxicity of continuous use.
  • Liver and kidney screening: ALT (alanine aminotransferase, a liver-cell enzyme), AST (aspartate aminotransferase, a related liver enzyme), bilirubin and eGFR before starting identify people at risk of the fourfold half-life prolongation.
  • Reduced frequency with organ impairment: The poisoning researchers recommended once-daily dosing for the first 3 days in severe poisoning to prevent accumulation when clearance was slowed (Aksenov, 1996).
  • Blood pressure and glucose checks: Home blood pressure and fasting glucose on days 1–3 detect theoretical hypotension (low blood pressure) or hypoglycemia early.
  • Bleeding precautions: Pausing antiplatelet supplements and NSAIDs, and stopping at least 7 days before surgery, reduces theoretical bleeding risk.
  • Daytime dosing: Morning dosing limits the sleep-shortening effect reported for the analog bemitil.

Therapeutic Protocol

  • No established longevity protocol: No practitioner, clinic or guideline uses Etomerzol for health or longevity. Every regimen below comes from Soviet and Russian military-clinical research, not from self-experimentation practice.
  • Clinical research regimen (Military Medical Academy, St. Petersburg): 2 mL of a 4% solution (80 mg) injected intramuscularly once or twice daily for 7–10 days, starting on day 1–2 of poisoning (Aksenov, 1996).
  • Severe-illness adjustment: For severe poisoning, the researchers recommended one daily injection for the first 3 days, then two daily for 7–10 days, because clearance slowed markedly (Aksenov, 1996); trial patients received one or two daily injections.
  • Oral route (animal-derived alternative, Plotnikov’s Tomsk group): Rats received 50 mg/kg orally for 10 days (Vaizova et al., 1994); body-surface scaling (standard animal-to-human dose conversion) gives roughly 8 mg/kg in humans, but no human oral dose has been tested.
  • Best time of day: Daytime dosing follows from bemitil’s sleep-shortening effect; no Etomerzol timing study exists.
  • Half-life: About 2 hours in healthy volunteers after intramuscular injection; 8–9 hours in poisoned patients; about 0.4 hours in rats (Aksenov, 1996).
  • Single versus split doses: The short human half-life led researchers to twice-daily injections (Aksenov, 1996); split dosing is the only tested pattern.
  • Genetic polymorphisms: No pharmacogenetic data exist; with metabolizing enzymes unidentified, no variant can guide dosing.
  • Sex: The poisoning study included 20 men and 14 women without sex-specific dosing or analysis (Aksenov, 1996).
  • Age: Participants averaged about 45 years (Aksenov, 1996); no data exist above 65, where slower clearance could justify lower frequency.
  • Baseline biomarkers: Benefits appeared where oxidative-stress, liver and kidney markers were abnormal; response with normal baselines is untested beyond the volunteer study.
  • Pre-existing conditions: Liver or kidney impairment prolonged half-life about fourfold, the reason researchers recommended reduced dosing frequency early in severe poisoning (Aksenov, 1996).

Discontinuation & Cycling

  • Short-term only: All human use has been 3–10 day courses. Lifelong or continuous use has never been studied.
  • Withdrawal effects: None reported after courses in volunteers or poisoned patients, and none described in animal studies.
  • Tapering: Not used or studied; research courses ended abruptly without reported problems.
  • Cycling: Soviet actoprotector practice used short courses around extreme loads. No evidence shows that cycling maintains efficacy or that tolerance develops with repeated courses.

Sourcing and Quality

  • No approved product: No pharmaceutical-grade Etomerzol is marketed anywhere. It is sold only as a research chemical labeled not for human use, for example by Smolecule.
  • Third-party testing: A batch-specific certificate of analysis with HPLC (high-performance liquid chromatography, a purity test) of at least 98%, plus mass-spectrometry or NMR (nuclear magnetic resonance) identity confirmation from an independent laboratory, verifies content.
  • Salt form and pH: The studied form is the hydrochloride salt, whose solutions are strongly acidic (pH about 3) and caused tissue injury when injected unbuffered.
  • Name confusion: Etomerzol differs from bemethyl (bemitil) and from etozolin, a diuretic (a drug that increases urine output); spelling variants (ethomersol, tomerzol) increase the risk of ordering the wrong compound.
  • No compounding option: No reputable compounding pharmacy is known to prepare Etomerzol. Sterile injectables prepared outside a pharmacy carry contamination and dosing-error risk.

Practical Considerations

  • Time to effect: In poisoning, benefits appeared from day 3–7 of treatment; in volunteers, effects appeared within a single 6-hour workload (Aksenov, 1996).
  • Common pitfalls: Scaling rat milligram-per-kilogram doses directly to humans; injecting unbuffered acidic solution; assuming bemitil data apply unchanged; trusting research-chemical purity without independent testing.
  • Regulatory status: Not approved by the FDA (U.S. Food and Drug Administration), the EMA (European Medicines Agency) or Russian authorities; clinical development stopped in 1991 (Oliynyk & Oh, 2012).
  • Anti-doping status: As a substance without regulatory approval, Etomerzol falls under category S0 (non-approved substances), prohibited at all times by the World Anti-Doping Agency Prohibited List.
  • Cost and accessibility: Available only in milligram research quantities from chemical suppliers, making human-scale dosing costly and hard to obtain.
  • Language barrier: Nearly all primary data are in Russian, often in abstracts or dissertations, which limits independent checking.

Interaction with Foundational Habits

  • Sleep: Indirect, potentially blunting. The analog bemitil shortens sleep and causes irritability through mild stimulation; Etomerzol is untested. Morning or early-afternoon dosing and a sleep diary or wearable during any course would reveal a disruption.
  • Nutrition: Indirect. Carbohydrate-rich food accelerates absorption of oral bemitil; no Etomerzol oral data exist. The class contraindication in low blood sugar argues caution during prolonged fasting. No nutrient depletion has been reported.
  • Exercise: Potentiating in design. Etomerzol aimed to sustain work capacity, and volunteers showed better endurance during 6–24 hour loads (Aksenov, 1996). Whether its antioxidant action blunts training adaptations, as vitamins C and E did in Ristow et al., 2009, is untested.
  • Stress management: Direct and protective in design. Developed for extreme physical stress (heat, oxygen shortage, poisoning); rats kept normal behavior after head trauma (Zarubina & Shabanov, 2005). No cortisol or human psychological-stress data exist.

Monitoring Protocol & Defining Success

Baseline testing before any course establishes liver, kidney, glucose, clotting-cell and blood pressure status, because impaired clearance prolonged the half-life about fourfold and the theoretical risks involve bleeding, low blood pressure and low blood sugar. Baseline values also give the individual reference for judging change.

Ongoing monitoring follows a set cadence: home blood pressure and fasting glucose daily on days 1–3, repeat liver and kidney panels at the end of each 7–10 day course, and a full repeat of the baseline panel before any further course, spaced at least 4–6 weeks apart. Success is defined by the target outcome itself (for example, recovery after a demanding event or improved endurance on a repeatable test), measured against the person’s own baseline, with no rise in liver enzymes or creatinine.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10–25 U/L Liver-cell injury Conventional upper limit about 40–55 U/L; avoid strenuous exercise 48 hours before testing
AST 10–25 U/L Liver and muscle injury Conventional upper limit about 40 U/L; rises after hard exercise, so pair with ALT
Total bilirubin 0.3–1.0 mg/dL Liver processing capacity Conventional range 0.1–1.2 mg/dL; Gilbert’s syndrome (a benign inherited bilirubin rise) raises it without injury
Creatinine with eGFR eGFR above 90 mL/min/1.73 m² Kidney clearance of the drug Conventional threshold for normal is above 60; high muscle mass raises creatinine, cystatin C (an alternative kidney marker) refines it
Fasting glucose 75–90 mg/dL Detects low or unstable blood sugar Conventional range 70–99 mg/dL; 8–12 hour fast, morning draw
Platelet count 150–350 ×10⁹/L Baseline clotting-cell supply Conventional range 150–450 ×10⁹/L; part of a complete blood count
Blood pressure Below 120/80 mmHg, systolic above 100 Detects additive lowering Seated, rested 5 minutes, same time daily; conventional normal below 130/80

Qualitative markers:

  • Sleep duration and quality compared with the pre-course baseline
  • Perceived exertion and recovery speed after a standardized workout
  • Injection-site pain, redness or hardening, if any injectable form is used
  • Nausea, stomach discomfort or headache
  • Mood, irritability and mental clarity
  • Unusual bruising, nosebleeds or bleeding gums

Emerging Research

  • Registered trials: ClinicalTrials.gov lists no study of Etomerzol under any spelling (searched 2026-09-30), so no NCT ID exists; no new human trial is known.
  • Organophosphate poisoning models: Rat work found Etomerzol more protective than metaprot (generic bemitil) after carbophos poisoning, restoring exercise tolerance, liver and kidney markers (Vorob’eva et al., 2012), strengthening the case for its original use.
  • Pharmacokinetic groundwork: Tissue-distribution studies in rats after single and repeated dosing (Sergeeva & Gulyaeva, 2008) supply a basis for human dosing models, but no modern human study using current analytical standards exists.
  • Weaker-than-comparator findings: In toxin-induced liver injury, Etomerzol ranked below the antioxidant dibunol and sodium oxybate (Dubovaia et al., 1996), and the injection complications halted development, findings that weaken the case.
  • Anti-doping scrutiny of Russian antihypoxants: A review of the related compound Hypoxen documents its 2023 addition to WADA (World Anti-Doping Agency) monitoring (Jędrejko et al., 2025); similar scrutiny could produce the first independent human data on this compound class.
  • Aging-specific endpoints: No study has tested Etomerzol in aged animals, on lifespan, or on aging biomarkers. Such work, independent of the developing institutions, could confirm or refute relevance to longevity.

Conclusion

Etomerzol is a Soviet-era synthetic compound, a close chemical relative of bemitil, designed to keep soldiers and patients functioning under oxygen shortage, heavy exertion and poisoning. For a health- and longevity-focused adult, it sits at the far edge of the evidence: an unapproved research chemical with no product, no practitioner protocol and no study connected to aging.

Its best-supported benefit is faster recovery after pesticide poisoning, seen in one small controlled study, which does not bear on healthy aging. Better endurance during very long workloads in healthy volunteers rests on a single, loosely controlled study. Brain, liver, immune and oxygen-shortage protection come from animal and cell experiments only.

The clearest recorded harm is tissue injury at the injection site from its strongly acidic solution. Other concerns, including bleeding tendency, lower blood pressure, low blood sugar and effects of long-term use, are theoretical or borrowed from its chemical relative, and the body removes the compound far more slowly when the liver or kidneys are impaired.

The evidence base is small, old, largely in Russian, never replicated internationally, and produced almost entirely by the military institutions that created the compound, which had an institutional interest in its adoption. For this audience, the balance is defined less by any demonstrated harm than by how little is known: modest short-term signals in extreme conditions, no long-term safety record, and no evidence on longevity itself.

Top - Benefits - Risks - Protocol